ASCO: J&J, Legend's Carvykti stages stellar show in earlier myeloma. But has the CAR-T reached a ceiling?
Fierce Pharma
JUNE 3, 2023
After a recent data leak reveale | After a recent data leak revealed a dramatic benefit for J&J and Legend’s Carvykti in earlier treatment of multiple myeloma, the pair has peeled back some even more stunning efficacy results that could further pressure Bristol Myers Squibb’s rival CAR-T therapy, Abecma.
Let's personalize your content